Navigation Links
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Date:5/7/2009

and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

The Company has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and it has advanced AZ-104 (Staccato loxapine) into Phase 2b testing. Both product candidates are being developed for the acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document. Clinical guidance is as of May 7, 2009 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of March 31, 2009.

This press release and anticipated conference call include forward-looking statements regarding the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
2. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
8. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
9. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
11. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ... developing therapeutics that address unmet medical needs in ... Elston will present at the Marcum MicroCap ... , 4:00 PM EDTLocation: , The Grand Hyatt, ... www.juniperpharma.com, under  ,Investor, or  click here ...
(Date:5/26/2015)... 26, 2015  PAREXEL International Corporation (NASDAQ: PRXL ... the Goldman Sachs Healthcare Conference in Palos Verdes, CA.  ... Officer, will be making a presentation on PAREXEL and ... June 9, 2015. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
(Date:5/26/2015)... 26, 2015  OrthoAccel ® Technologies, Inc., the leader ... growth accelerating in response to continued demand from orthodontists ... available in 2,500 practice locations in the U.S. and ... AcceleDent ® is the only FDA-cleared Class II ... orthodontic treatment by as much as 50 percent.  ...
Breaking Medicine Technology:Juniper Pharmaceuticals to Present at Investor Conference on May 28, 2015 2PAREXEL International To Present At Goldman Sachs Healthcare Conference 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3
... FARMINGDALE, N.Y., Nov. 2, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative therapeutic ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic ...
... 2011 Perrigo Company (Nasdaq: PRGO ; TASE) ... Drug Administration (FDA) a New Drug Application (NDA) for testosterone ... the owner of the Reference Listed Drug of its filing. ... the United States District Court for the District of New ...
Cached Medicine Technology:Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 2Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 3Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott 2
(Date:5/26/2015)... Abington is pleased to announce ... practice with seven medical professionals, has joined Abington ... site in the United States to be recognized ... the National Committee for Quality Assurance. , Family ... sick care – including routine gynecology care and ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 Two ... recently joined Dr. Marissa Pei on a ... conversation focusing on addiction. Aired on KCAA AM 1050, ... Deena Duncan, marriage and family therapist, as they discuss ... estimated to affect more than 23.5 million Americans. The ...
(Date:5/26/2015)... 2015 CIO Review has chosen SIGNiX ... and Life Sciences Technology Solution Providers. The positioning is based ... solution which is applicable across the entire security spectrum of ... broad adoption. , “SIGNiX has been on our radar ... and Life Sciences Technology space, and we are happy to ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week is ... by the Substance Abuse and Mental Health Services Administration ... action about, substance abuse as well as mental health ... to join in promoting prevention strategies, in educating other ... building community partnerships. , The Voice of One, the ...
(Date:5/26/2015)... Scientists at the University of Pennsylvania believe they ... patients benefit from immunotherapy; surgery may be the key. ... new research. Click here to read it now. ... and pulmonology theorized that, because large mesothelioma tumors have ... drugs might work better if the tumor size could ...
Breaking Medicine News(10 mins):Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2
... December 14, 2011 Elsevier, a world-leading provider of ... the Federation of Biochemical Societies (FEBS) announced today the ... access journal. The journal is dedicated to publishing articles ... health and disease. In launching this new journal, ...
... Valencia in Spain have analysed fresh orange juice squeezed ... 43% of samples exceeded the acceptable enterobacteriaceae levels laid ... handled correctly, that juicers are washed properly and that ... stored in metal jugs. ,Around 40% of the ...
... Matej Oreič from VTT Technical Research Centre of Finland ... signature indicative of hypoxia and up-regulated pentose phosphate pathway. ... assay from a serum sample months or even years ... a healthcare setting, the application of such an assay ...
... The two main ways to prevent and control influenza ... of investigators has found that statins, cholesterol-lowering drugs, may ... reduce mortality among patients hospitalized with influenza. The findings ... and are now available online. In an ...
... muscular dystrophy also have a higher risk of getting cancer, ... of the American Medical Association . The team found ... risk primarily for four types of cancer: brain, ovary, colon, ... also found a possible increased risk for some other types ...
... December 13, 2011 The American Cancer Society has ... transparency, consistency, and rigor in creating guidance about ... principles from the Institutes of Medicine (IOM) by ... guidelines, commissioning systematic evidence reviews, and clearly articulating ...
Cached Medicine News:Health News:Elsevier and Federation of Biochemical Societies launch new journal 2Health News:Microbial contamination found in orange juice squeezed in bars and restaurants 2Health News:Biochemical signature predicts progression to Alzheimer's disease 2Health News:Statins may reduce mortality in patients hospitalized with influenza 2Health News:Some muscular dystrophy patients at increased risk for cancer 2Health News:American Cancer Society revises cancer screening guideline process 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: